ライフサイエンスコーパス: vincristine

1 at included treatment with 36 to 39 doses of vincristine.

2 ng treatment with doxorubicin, etoposide and vincristine.

3 n the centroblast subtype to doxorubicin and vincristine.

4 ensive anti-cancer compounds vinblastine and vincristine.

5 spect to discontinuation of bleomycin and/or vincristine.

6 luding the anti-cancer drugs vinblastine and vincristine.

7 eukemia cells increased their sensitivity to vincristine.

8 utinib did not alter the pharmacokinetics of vincristine.

9 which the anti-cancer drugs vinblastine and vincristine.

10 er before and (18)F-FDG after treatment with vincristine.

11 en therapeutic plasma exchange alone or with vincristine.

12 c drugs, including paclitaxel (Taxol(R)) and vincristine.

13 of eight cycles of cisplatin, lomustine, and vincristine.

14 nt and in combination with dexamethasone and vincristine.

15 ating with cyclophosphamide, idarubicin, and vincristine.

16 ignificant anticancer agents vinblastine and vincristine.

17 (EdU), and then treated each population with vincristine.

18 nated axons in the sural nerve and toe after vincristine.

19 opathy induced by the chemotherapeutic agent vincristine.

20 00 ng/mL), doxorubicin (4 to 100 ng/mL), and vincristine (0.5 to 4 ng/mL), drugs commonly involved in

21 Nine animals were treated with vincristine (0.75 mug/g/d).

22 phamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) (maximum dose 2 mg), and rituxim

23 nous doxorubicin 50 mg/m(2), and intravenous vincristine 1.4 mg/m(2) [maximum 2.0 mg] all on day 1 of

24 (1:1) by a minimisation technique to receive vincristine 1.5 mg/m(2) at weeks 1-8, 11, 12, 14, 15, 17

25 mg/m(2), and DL2: 50 mg/m(2)), combined with vincristine 1.5 mg/m(2) on days 1 and 8, temozolomide 10

26 [750 mg/m(2)], doxorubicin [50 mg/m(2)], and vincristine [1.4 mg/m(2), up to 2 mg] all on day 1, and

27 phamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 2 mg, rituximab 375 mg/m(2) on day 1, and or

28 Patients received vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclo

29 In constrast with paclitaxel and vincristine, 3.1a is devoid of astrocyte toxicity.

30 patients receiving </= or > three cycles of vincristine (5-year PFS difference, -1.3%; 95% CI, -5.6%

31 re treated with chemotherapy based on either vincristine, actinomycin, and cyclophosphamide or vincri

32 istine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide-based chemother

33 AD (rituximab fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone), RCHOP+HDT/A

34 predominantly axonal damage: Paclitaxel and vincristine affected mostly large myelinated fibers, bor

35 carbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initi

36 MRP1 and accumulation of the cytotoxic drug vincristine, an MRP1 substrate, depleted virus from natu

37 ed 4 weeks of preoperative chemotherapy with vincristine and actinomycin D.

38 EC chemotherapy with a 5-drug combination of vincristine and carboplatin, alternating with cyclophosp

39 ved consolidation chemotherapy consisting of vincristine and cyclophosphamide.

40 phosphamide dose, 26.4 g/m(2)) compared with vincristine and dactinomycin (VA) for patients with subs

41 e may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin,

42 cs were governed by the protonation state of vincristine and doxorubicin and were tunable based on si

43 phalan alone dropped from 32.0% to 4.1%, and vincristine and doxorubicin use declined from 18.2% to 0

44 s were studied with cationic oncology drugs, vincristine and doxorubicin, with a focus on hydrophobic

45 ed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro.

46 ogy Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI).

47 roteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase i

48 maintenance with ponatinib 45 mg daily with vincristine and prednisone monthly for 2 years followed

49 indole alkaloid (MIA)-type anticancer drugs vincristine and vinblastine, we identified a jasmonate-r

50 ids (TIAs), including the chemotherapeutics, vincristine and vinblastine.

51 ission induction therapy with dexamethasone, vincristine, and asparaginase, without anthracyclines.

52 ressive options, including cyclophosphamide, vincristine, and cyclosporine.

53 domly assigned to receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combin

54 ver 70 years) with intrathecal chemotherapy, vincristine, and dexamethasone during induction.

55 ne, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate d

56 sed use of common chemotherapies (melphalan, vincristine, and doxorubicin), novel agents (thalidomide

57 doses of pegylated asparaginase, 18 doses of vincristine, and escalated-dose intravenous methotrexate

58 n (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vi

59 ty to daunorubicin, paclitaxel, vinblastine, vincristine, and etoposide.

60 ly important chemotherapy drugs vinblastine, vincristine, and other synthetic derivatives that are de

61 ombination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks impro

62 tention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen withou

63 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) to uncover molecu

64 of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients consi

65 of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) r

66 as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (58%), with local radiation

67 e compared with rituximab, cyclophosphamide, vincristine, and prednisone (adjusted HR, 0.94; 95% CI,

68 treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +/- rituximab were us

69 etoposide to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and upfront consolida

70 our cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a sta

71 six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy at 3-wee

72 s of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus inv

73 ive cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus rituxima

74 outcome after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (HREFS

75 imens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard f

76 with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy.

77 evaluation of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab in NLP

78 Compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), initial therapy with

79 imens, namely cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent t

80 n used in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly

81 utuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP; every 3 weeks for 6

82 acodynamics of GP2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CVP) with rituximab-

83 th rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (P = .037), independent of c

84 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at the British Colu

85 imab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, we as

86 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rate

87 of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days.

88 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 t

89 to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in prev

90 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-

91 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like ther

92 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure.

93 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were assembled on t

94 th rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were studied using

95 rd rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail

96 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) w

97 of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

98 is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

99 ng rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

100 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

101 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

102 bination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

103 y consisting of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP).

104 R (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + high-dose therapy/autologo

105 ght cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or eight cycles of cy

106 (treated with cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP], n = 270; treated wit

107 [CHOP] or eight cycles of cyclophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during

108 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus c

109 [R-CHOP] or rituximab plus cyclophosphamide, vincristine, and prednisone [R-CVP]) for treatment-naive

110 six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone administered at an interval

111 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxo

112 th rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone compared with rituximab, cyc

113 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone delivered in a 21-day cycle

114 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-

115 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 21 days with int

116 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone on a 14-day schedule (6xR-CH

117 of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, pre

118 CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dos

119 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fl

120 P (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Can

121 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

122 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy: screen all pa

123 P (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in p

124 dnisone and 6 cyclophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL.

125 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggres

126 mab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like therapies, and

127 cles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT)

128 P (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituxima

129 % response to initial COP (cyclophosphamide, vincristine, and prednisone) therapy.

130 ared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus

131 P (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

132 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone); this new combination is kn

133 FL treated with rituximab, cyclophosphamide, vincristine, and prednisone, and a clinical trial valida

134 ituximab, a combination of cyclophosphamide, vincristine, and prednisone, or bendamustine.

135 otherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without melatonin.

136 ituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

137 survival over cyclophosphamide, doxorubicin, vincristine, and prednisone.

138 -week cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone (CHOP-14) was d

139 es to spindle poisons, including nocodazole, vincristine, and Taxol.

140 es to paclitaxel, doxorubicin, mitoxantrone, vincristine, and trabectedin with no effect on cell sens

141 ed cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemothera

142 was to characterize paclitaxel-, cisplatin-, vincristine- and bortezomib-induced neuropathy in C57BL/

143 tabolites that includes the anticancer agent vincristine, antimalarial quinine and neurotoxin strychn

144 Vinblastine and vincristine are condensed from the monoterpenoid indole

145 itumor substances related to vinblastine and vincristine are exclusively found in the Catharanthus ro

146 HOP or in combination with CHP (CHOP without vincristine) as front-line treatment in patients with CD

147 r for the anti-cancer agents vinblastine and vincristine, as well as other biologically active compou

148 Treatment with vincristine at a dose of 1.5 or 2.0 mg/m2.

149 CNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib

150 versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, predniso

151 athway appear to be a feature of vinblastine/vincristine biosynthesis.

152 ine, melphalan, cyclophosphamide, prednisone/vincristine, bischloroethylnitrosourea, adriamycin, and

153 r mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone (Stanf

154 ne (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and pred

155 a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rh

156 Conclusion Topotecan combined with vincristine, carboplatin, and aggressive focal therapies

157 ive PETHEMA/GEM trials: GEM2000 [VBMCP/VBAD (vincristine, carmustine, melphalan, cyclophosphamide, pr

158 ekly intraperitoneal injections of 1.5 mg/kg vincristine cause pronounced mechanical and heat hyperal

159 ddition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patie

160 randomly assigned to receive carboplatin and vincristine (CV) or thioguanine, procarbazine, lomustine

161 d continuous-infusion etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus with

162 dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achi

163 dnisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.

164 inations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, an

165 roved failure-free survival (FFS) rates with vincristine, dactinomycin, and cyclophosphamide (VAC; to

166 mbination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v

167 istology Wilms tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiatio

168 treated with 3-drug induction chemotherapy (vincristine, dactinomycin, and doxorubicin) for 6 or 12

169 rative chemotherapy consisting of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin

170 , dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after a

171 treatment of ibrutinib with dexamethasone or vincristine demonstrated synergistic activity against pr

172 onsisted of pegylated asparaginase on day 4; vincristine, dexamethasone (alternate weeks), and doxoru

173 odified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) induction chemoimm

174 ivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against P

175 rafts compared with a combination regimen of vincristine, dexamethasone, and l-asparaginase.

176 owed that the combination of bortezomib with vincristine, dexamethasone, pegylated asparaginase, and

177 Maintenance therapy was dasatinib and vincristine/dexamethasone reinductions for 18 months fol

178 Bleomycin and vincristine discontinuation because of drug-specific adv

179 2) was associated with impaired flexibility, vincristine dose >/=39 mg/m(2) with peripheral neuropath

180 reduced by 30% for dexamethasone and 50% for vincristine, doxorubicin, and cyclophosphamide, which sh

181 nd randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) versu

182 ycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD)

183 on and lenalidomide in maintenance), and the vincristine, doxorubicin, and dexamethasone (VAD) group

184 y assigned to receive induction therapy with vincristine, doxorubicin, and dexamethasone (VAD) or bor

185 rst-line hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating

186 B-DLBCLs in both the CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone) and the rituxi

187 a prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfam

188 Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-

189 the IFM 2005-01 (bortezomib-dexamethasone v vincristine-doxorubicin-dexamethasone [VAD] induction),

190 ed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders receiv

191 tandard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) i

192 alternating weekly with cyclophosphamide and vincristine (EMA/CO).

193 2 groups: group A patients were treated with vincristine, etoposide, and carboplatin (VEC) and group

194 High-dose chemotherapy with a combination of vincristine, etoposide, and carboplatin in patients with

195 Following IVC (vincristine, etoposide, and carboplatin), adjuvant treat

196 weekly CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) was administered

197 chemotherapy: two courses of topotecan plus vincristine followed by three alternating administration

198 ncristine for two courses and topotecan plus vincristine for one course, with optional periocular car

199 ternating administrations of carboplatin and vincristine for two courses and topotecan plus vincristi

200 ating with cyclophosphamide, idarubicin, and vincristine, for stage III retinoblastoma.

201 ing the low-level anticancer vinblastine and vincristine, for which the late biosynthetic steps occur

202 intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VID

203 zed, bleomycin was discontinued in 17.6% and vincristine in 32.6%.

204 stigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab,

205 The role of bleomycin and vincristine in the treatment of patients with advanced H

206 rted NMNAT2-specific neuroprotection against vincristine-induced cell death while four selected NMNAT

207 Using traumatic and vincristine-induced injury models in neurons, we demonst

208 Grade 2 to 4 vincristine-induced neuropathy during continuation thera

209 Vincristine-induced peripheral neuropathy was assessed a

210 e-nucleotide polymorphism (SNP) analysis and vincristine-induced peripheral neuropathy were assessed

211 ay be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possib

212 redominant axonal polyneuropathy that mimics vincristine-induced peripheral polyneuropathy in humans.

213 deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice.

214 ing this pathway prevents the development of vincristine-induced peripheral polyneuropathy.

215 Thus, vincristine induces distinct death programs in primary A

216 Infusional etoposide, prednisone, infusional vincristine, infusional doxorubicin, and cyclophosphamid

217 astoma cells that were treated with Taxol or vincristine inhibited activation of calpain and the redu

218 dria in neuronal cells, whereas eribulin and vincristine inhibited transport only at significantly hi

219 Liposomal vincristine is also approved for relapsed disease.

220 HL60 leukemic cells following treatment with vincristine is not explained by Darwinian selection but

221 Treatment with vincristine led to reduced tumor growth, which was effic

222 ckdown in combination with either ABT-737 or vincristine markedly reduced leukemia burden in mice and

223 atment of acute leukemia (e.g., doxorubicin, vincristine, mitoxantrone, and methotrexate), have been

224 ormation, had a significant association with vincristine neuropathy (meta-analysis P = 6.3x10(-9)).

225 l that subacute/chronic axon loss induced by vincristine occurs via a SARM1 mediated axonal destructi

226 actinomycin followed by cyclophosphamide and vincristine on alternating weeks (EMA-CO) with an SIR of

227 ous doxorubicin, and 1.4 mg/m(2) intravenous vincristine on day 1, and 40 mg/m(2) oral prednisone on

228 phoblastic leukemia (ALL) cells treated with vincristine only weakly exhibited colocalization between

229 ALL cells that developed resistance against vincristine or nilotinib, drugs with distinct cytotoxic

230 plasma exchange; pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy a

231 val benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation

232 gating adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendro

233 f six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).

234 mly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone

235 ytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted in significantly

236 tuximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prosp

237 imens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year o

238 evacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab (R-CHOP) w

239 or rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14) induction and a posit

240 rapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone or cyclophosphamide, vincristine

241 4 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) followed by 3 cycles of ICE (if

242 vincristine, prednisone or cyclophosphamide, vincristine, prednisone), Follicular Lymphoma Internatio

243 mab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enr

244 onal two or four cycles of cyclophosphamide, vincristine, prednisone, and procarbazine were added in

245 side, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and

246 side, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and

247 side, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) in pati

248 prednisone, procarbazine, and doxorubicin or vincristine, prednisone, etoposide, and doxorubicin chem

249 1 (TG1; early stages) received two cycles of vincristine, prednisone, procarbazine, and doxorubicin o

250 has involved cyclophosphamide, doxorubicin, vincristine, prednisone-based therapy followed by consol

251 th rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

252 under rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) chemotherapy showed a ra

253 ere treated with three cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC).

254 py (rituximab, high-dose methotrexate [MTX], vincristine, procarbazine) followed by a novel consolida

255 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP basel

256 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) a

257 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for

258 Primary chemotherapy was mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or proc

259 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline ov

260 in, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by t

261 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) has significa

262 in, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in the German

263 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycl

264 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone).

265 n, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, menstrual act

266 sine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; C

267 combination of procarbazine, lomustine, and vincristine provide survival benefit.

268 s of asparaginase exposure and dexamethasone/vincristine pulses) compared with historical controls (7

269 sphamide, adriamycin, prednisone, and either vincristine (R-CHOP) or bortezomib (VR-CAP).

270 f rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-do

271 methotrexate (3.5 g/m(2)), procarbazine, and vincristine (R-MPV).

272 sociated with increased risk and severity of vincristine-related peripheral neuropathy.

273 rove their chemosensitizing action on KBvin (vincristine-resistant nasopharyngeal carcinoma) cells, a

274 dependent P-gp overexpressing cell line, the vincristine-resistant VK2, allowed us to reclassify six

275 our cycles of bleomycin or > three cycles of vincristine, respectively.

276 ess the effects of lower CEP72 expression on vincristine sensitivity.

277 that is induced by the chemotherapeutic drug vincristine sulfate (VCR).

278 Vincristine sulfate liposome injection (VSLI), sphingomy

279 Systemic chemotherapy with vincristine sulfate, etoposide, and carboplatin had fail

280 ximab-cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, prednisone (CHOP) or rituximab-CHOP

281 etastasis in high-risk patients treated with vincristine sulphate, etoposide phosphate, and carboplat

282 ay for 5 days was the MTD when combined with vincristine, temozolomide and bevacizumab administered o

283 irinotecan administered in combination with vincristine, temozolomide and bevacizumab in children wi

284 nt with multiagent chemotherapy-carboplatin, vincristine, temozolomide, procarbazine, lomustine, and

285 s of microtubules and the drugs eribulin and vincristine that bind at microtubule ends, on mitochondr

286 and 218 (6.6%) received </= three cycles of vincristine; these were compared with patients receiving

287 ke, indicating that the cytotoxic effects of vincristine took place during G1 Conversely, cells isola

288 or thioguanine, procarbazine, lomustine, and vincristine (TPCV).

289 symptoms developed faster in paclitaxel and vincristine treated animals compared to cisplatin and bo

290 with other types of axonal insults, such as vincristine treatment and intraocular pressure elevation

291 Using the same regimen of vincristine treatment in SARM1 knockout mice, the develo

292 cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib

293 ocks axon degeneration induced by axotomy or vincristine treatment, while SARM acts in parallel with

294 f life, including peripheral neuropathy from vincristine treatment.

295 carboplatin (30-45 mg/m(2)/dose), along with vincristine (VCR) once per week for 6 weeks.

296 Moreover, co-treatment with ATM and vincristine (VCR), a microtubule inhibitor currently use

297 anticancer drugs, such as paclitaxel (TAX), vincristine (VCR), and doxorubicin (DOX).

298 , sphingomyelin and cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification

299 noid indole alkaloids (TIAs) vinblastine and vincristine, which are used in cancer chemotherapy.

300 icrotubule-destabilizing drugs, eribulin and vincristine, which bind preferentially to microtubule en

301 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per squa